L'intérêt à découvert pour DexCom donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de DexCom. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

DexCom (NASDAQ:DXCM) Stock, Rapport sur les intérêts à découvert

DEXCOM INC

DexCom

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

DexCom Inc

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $82 to $102.

News

Price Target

Analyst Ratings

DXCM

Citigroup Maintains Buy on DexCom, Raises Price Target to $102

<figure class="wp-block-image aligncenter size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081653/Top-Image-1024x683.png" alt="" class="wp-image-13068" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081653/Top-Image-1024x683.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081653/Top-Image-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081653/Top-Image-768x512.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081653/Top-Image.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">A Threat To The Diabetes Cash Cow</h2>
Years ago, in a conversation with an endocrinologist, I mentioned there was no incentive to cure diabetes, giving the money companies were making from managing it (with testing supplies, insulin, etc.). He replied that the incumbents had no incentive to cure it, but a startup company would. Now it looks like one has—at least in one patient. Sana Biotechnology, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) has developed a one-time treatment that could upend the entire diabetes industry.
<h2 class="wp-block-heading">How It Works</h2>
Type 1 diabetes occurs when the immune system destroys the pancreatic beta cells, which are responsible for producing insulin. While transplants of donor islets—clusters of cells that include beta cells—can restore insulin production, they require scarce donor tissue and lifelong immunosuppressive drugs, which carry serious risks. As a result, insulin remains the only practical treatment for nearly all Type 1 diabetics.&nbsp;Sana has successfully engineered donor-derived islets to evade immune rejection, enabling a Type 1 diabetic to produce his own insulin, without the need for immunosuppressive drugs.
This isn't just theory. In a clinical trial at Uppsala University in Sweden, Sana's genetically engineered pancreatic islets were injected into the forearm of a Type 1 diabetic. As the company noted in its annual report, this patient is now&nbsp;more than three months post-treatment, making his own insulin for the first time in 30 years—with no immunosuppressive therapy.
A recent presentation by Sana shows the results of this experiment so far. The C-peptide mentioned there is a biomarker of insulin production.
<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="578" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081738/Clinical-Results-1024x578.jpg" alt="" class="wp-image-13069" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081738/Clinical-Results-1024x578.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081738/Clinical-Results-300x169.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081738/Clinical-Results-768x433.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081738/Clinical-Results.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Slides from Sana's <a href="https://ir.sana.com/static-files/1f3a1d8c-24eb-4695-9380-747332ddae2a">May 2025 Corporate Presentation</a>.</figcaption></figure>
As the subsequent slide in the presentation shows, the patient was producing no insulin before the procedure, but has been producing insulin consistently since.
<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="580" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081849/C-Peptide-Slide-1024x580.jpg" alt="" class="wp-image-13070" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081849/C-Peptide-Slide-1024x580.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081849/C-Peptide-Slide-300x170.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081849/C-Peptide-Slide-768x435.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081849/C-Peptide-Slide.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">The Plan For Mass Production</h2>
The islet cells used in that trial came from a cadaveric donor. Sana's goal is to scale this breakthrough using&nbsp;stem cell–derived islets—which contain insulin-producing beta cells—that can be manufactured in large quantities and delivered off the shelf. The result would be a&nbsp;one-time treatment&nbsp;that could eliminate the need for insulin, blood sugar monitoring, and other diabetes therapies.
<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="575" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081940/One-time-treatment-1024x575.jpg" alt="" class="wp-image-13071" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081940/One-time-treatment-1024x575.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081940/One-time-treatment-300x169.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081940/One-time-treatment-768x431.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19081940/One-time-treatment.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Larger dose‑escalation cohorts under way, with 6‑ and 12‑month read‑outs expected over the next year.
<h3 class="wp-block-heading">The Potential Market Impact</h3>
If the current results hold up, Sana's therapy would convert Type‑1 diabetes from a&nbsp;chronic drug‑and‑device market&nbsp;into a&nbsp;one‑time cell‑therapy market—a seismic shift for incumbents.
<figure class="wp-block-image aligncenter size-full"><img loading="lazy" decoding="async" width="963" height="547" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082028/Market-Impact.png" alt="" class="wp-image-13072" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082028/Market-Impact.png 963w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082028/Market-Impact-300x170.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082028/Market-Impact-768x436.png 768w" sizes="(max-width: 963px) 100vw, 963px" /></figure>
As you can see above, diabetes therapies comprise 75% of Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) sales and 43% of Ely Lilly and Company&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>). For DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) and Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), diabetes is pretty much their entire businesses.
<h2 class="wp-block-heading">The Timeline That Matters</h2>
Some potential milestones to keep in mind for Sana headlines that could impact the diabetes therapy industry.
<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="527" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082137/Timeline-1024x527.png" alt="" class="wp-image-13073" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082137/Timeline-1024x527.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082137/Timeline-300x154.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082137/Timeline-768x395.png 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082137/Timeline.png 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">The Bottom Line</h2>
Sana has not&nbsp;cured&nbsp;diabetes yet—but a&nbsp;&gt; 3‑month insulin‑free human case without immunosuppression&nbsp;is more evidence than the market usually prices into chronically‑treated franchises. Shareholders of the incumbent companies mentioned above ought to consider hedging. The Portfolio Armor iPhone app can help you find the least expensive hedge that fits your risk tolerance and time frame. You can download it by aiming your iPhone camera at the QR code below (or by&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">tapping here</a>, if you are reading this on your iPhone).
<figure class="wp-block-image size-large"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082314/PA-JPEG-5-1024x683.jpeg" alt="" class="wp-image-13074" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082314/PA-JPEG-5-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082314/PA-JPEG-5-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082314/PA-JPEG-5-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082314/PA-JPEG-5.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Enterprising investors might also consider adding a small position in SANA. There's asymmetric upside potential if follow‑up cohorts validate the initial results. My subscribers and I bought shares in the company earlier this year, and then LEAPS on it last week, now that the stock has options traded on it.
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/p/trade-alert-pharma-panic"><img loading="lazy" decoding="async" width="917" height="617" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082502/Trade-Alert.jpg" alt="" class="wp-image-13076" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082502/Trade-Alert.jpg 917w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082502/Trade-Alert-300x202.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082502/Trade-Alert-768x517.jpg 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
Our LEAPS expire in January, 2027.
If you want a heads up when we place our next trade, you can subscribe to the Portfolio Armor trading Substack below.&nbsp;
If you&#8217;d like to stay in touch
You can scan for optimal hedges for individual securities, find our current top ten names, and&nbsp;create hedged portfolios&nbsp;on&nbsp;<a href="https://portfolioarmor.com/">our website</a>.&nbsp;You can also follow Portfolio Armor on X&nbsp;<a href="https://twitter.com/portfolioarmor">here</a>, or become a free subscriber to our trading Substack using the link below (we&#8217;re using that for our occasional emails now).
<figure class="wp-block-image aligncenter size-full"><a href="https://portfolioarmor.substack.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082648/Widget-5.jpg" alt="" class="wp-image-13077" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082648/Widget-5.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19082648/Widget-5-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Biotech

Equities

Options

Opinion

Trading Ideas

PODD

SANA

The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants

Management

Dexcom Promotes Jake Leach To President And COO

DexCom's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NYSE">DXCM</a>) short percent of float has fallen 3.61% since its last report. The company recently reported that it has 10.61 million shares sold short, which is 3.47% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.97 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>DexCom Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746626419_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for DexCom has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing DexCom's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, DexCom's peer group average for short interest as a percentage of float is 4.19%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What's Driving the Market Sentiment Around DexCom?

Barclays analyst Matt Miksic maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Equal-Weight and raises the price target from $90 to $93.

Barclays Maintains Equal-Weight on DexCom, Raises Price Target to $93

These large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) shares rose 27.39% after the company reported better-than-expected financial results and raised <a href="https://www.benzinga.com//node/45149547" target="_blank" rel="noreferrer noopener">its FY25 sales guidance</a>. Several analysts <a href="https://www.benzinga.com/quote/duol/analyst-ratings" target="_blank" rel="noreferrer noopener">boosted the price forecast</a>.</li>
<li>CoreWeave, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) shares increased 24.15%.</li>
<li>Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) stock escalated 21.24% after the company reported better-than-expected financial results and raised <a href="https://www.benzinga.com//node/45061907" target="_blank" rel="noreferrer noopener">its FY25 adjusted EPS guidance</a>. Many analysts <a href="https://www.benzinga.com/quote/thc/analyst-ratings" target="_blank" rel="noreferrer noopener">boosted the price forecast</a>.</li>
<li>Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) stock upped 19.10% after it reported better-than-expected first-quarter financial results<a href="https://www.benzinga.com//node/45135625" target="_blank" rel="noreferrer noopener"> and raised its FY25 guidance</a>.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock upped 18.90%. Akeso, Inc. announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a second indication based on the results of the Phase 3 <a href="https://www.benzinga.com//node/45046531" target="_blank" rel="noreferrer noopener">trial, HARMONi-2 or AK112-303</a>.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) stock upped 18.31% last week after the company announced it launched its commercial self-driving <a href="https://www.benzinga.com//node/45128218" target="_blank" rel="noreferrer noopener">trucking service in Texas</a>.</li>
<li>Arista Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) shares were up 16.83% after Rosenblatt upgraded the stock from Sell to Neutral and raised its <a href="https://www.benzinga.com/quote/anet/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from $55 to $85</a>.</li>
<li>Trane Technologies plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) stock grew 14.83% after the company reported better-than-expected financial results and raised its FY25 GAAP EPS and <a href="https://www.benzinga.com//node/45108290" target="_blank" rel="noreferrer noopener">sales guidance above estimates</a>. Many analysts <a href="https://www.benzinga.com/quote/tt/analyst-ratings" target="_blank" rel="noreferrer noopener">boosted the price forecast</a>.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares escalated 13.90% f<a href="https://www.benzinga.com//node/45149628" target="_blank" rel="noreferrer noopener">ollowing strong quarterly sales</a>. Many analysts <a href="https://www.benzinga.com/quote/dxcm/analyst-ratings" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
<li>XPO Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) shares increased 13.81%  after the company reported better-than-expected <a href="https://www.benzinga.com//node/45099967" target="_blank" rel="noreferrer noopener">first-quarter EPS results</a>. Many analysts <a href="https://www.benzinga.com/quote/xpo/analyst-ratings" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
</ol>
Photo by DANIEL CONSTANTE via Shutterstock

Large Cap

Movers

ANET

CARR

CRWV

DUOL

EXAS

SMMT

Duolingo, CoreWeave And DexCom Are Among Top 10 Large-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?

U.S. stocks powered higher Friday after signs emerged that China may be open to negotiating a resolution to the fentanyl crisis, signaling a potential softening of trade tensions with the U.S. <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45172683/wall-street-eyes-9th-straight-day-of-gains-apple-falls-as-chinese-sales-disappoint-whats-driving-markets-friday">and lifting investor sentiment.</a>
Sources close to the Wall Street Journal <a href="https://www.wsj.com/world/china/beijing-weighs-fentanyl-offer-to-u-s-to-start-trade-talks-287cf233">revealed </a>that Wang Xiaohong, China's minister of public security and a senior cabinet member, has been inquiring about what President Donald Trump's team expects from China regarding its role in the production of fentanyl precursors.
The inquiry marks a possible turning point in the long-standing diplomatic standoff between Washington and Beijing.
<h3 class="wp-block-heading">Markets Cheer Diplomatic Hopes</h3>
The S&amp;P 500 Index jumped 1.5% to 5,685 points, on the way to its ninth straight day of gains and returning to levels last seen in late March.
Since hitting a short-term bottom in April, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) has rallied 17.5%, showcasing the index's strong recovery and renewed investor confidence.
The Nasdaq 100 rose even more aggressively during Friday trading, climbing 1.7% and above 20,100 points, driven by surging tech stocks. The index now trades at highs last seen on March 26.
Small caps staged an even sharper rebound. The Russell 2000 index – tracked by the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) – rallied 2.3% to 2,020 points, erasing losses incurred after the April 2 tariff announcements. 
<h3 class="wp-block-heading">Beijing's Strategy: Leverage Fentanyl To Reset Trade Talks?</h3>
According to people familiar with the matter, China is exploring the possibility of sending Wang Xiaohong to the U.S. or arranging a high-level meeting with U.S. officials in a neutral location. 
The talks are described as fluid, but one consistent thread is that Beijing is seeking reciprocal movement from Washington on tariffs, WSJ reports.
The gesture could open the door to wider negotiations. On Friday, China's Commerce Ministry shifted its tone, stating that it was considering beginning discussions with the U.S. to halt the ongoing trade war. 
This marked a notable departure from its earlier stance, where it demanded that the U.S. first roll back tariffs as a precondition for any dialogue.
The thaw in rhetoric comes at a critical moment for China's economy, which is grappling with a prolonged real estate slump, falling prices and subdued business sentiment. 
<h3 class="wp-block-heading">Tech Stocks Lead Friday&#8217;s Rally</h3>
Several large-cap tech names were at the forefront of the Nasdaq's rally. Among the top gainers:
<ul>
<li>DexCom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) soared 15% to $80.80</li>
<li>AppLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) gained 8.99% to $304.61</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) advanced 6.32% to $122.69</li>
<li>Old Dominion Freight Line Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) climbed 5.84% to $159.35</li>
<li>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) rose 5.7% to $122.83</li>
</ul>
Among the worst performers were:
<ul>
<li>Atlassian Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>), down 6.71% to $213.69</li>
<li>Take-Two Interactive Software Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>), off 5.62% to $221.95</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), slipping 4% to $204.78</li>
<li>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), falling 2.53% to $276.59</li>
<li>MercadoLibre Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), down 1.46% to $2,261.06</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45164558/us-adds-177000-jobs-in-april-topping-forecasts-as-economy-navigates-tariff-impact">April Jobs Blow Past Expectations, But Tariff Storm May Be Brewing</a></li>
</ul>
Photo: Shutterstock

Government

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Economics

Tech

ETFs

AAPL

AMGN

MELI

ODFL

PLTR

TEAM

TTWO

Nasdaq 100 Leads Wall Street Rally As China Signals Openness To Fentanyl Talks, Easing Trade Tensions

U.S. stocks advanced across the board by midday Friday, with the S&amp;P 500 eyeing its ninth consecutive day of gains—poised for the longest winning <a href="https://www.benzinga.com/markets">streak since May 2024.</a>
Risk appetite remained firm, underpinned by solid corporate earnings and a stronger-than-expected April jobs report. Nonfarm payrolls rose by 177,000, beating expectations of 130,000 and easing concerns over tariff-related hiring slowdowns.
All eleven S&amp;P 500 sectors traded in positive territory, led slightly by financials over technology. Major indexes have now fully recovered from the declines sparked on April 2, when President Donald Trump announced sweeping tariffs across trading partners.
The Nasdaq 100 climbed to levels last seen in late March, capping a strong week for tech stocks. Among the Magnificent Seven, all were on pace to close the week higher except Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), which slipped 4% as strong earnings were overshadowed by weaker sales in China.
The U.S. dollar index resumed its decline, pressured by renewed calls from President Trump for the Federal Reserve to lower interest rates ahead of next week's policy meeting.
Treasury yields surged following the upbeat jobs data, with the 10-year note jumping 10 basis points to 4.31%, easing recession concerns entering the second quarter.
In commodities, oil prices fell back to $58 per barrel despite Thursday's rally on heightened geopolitical tensions in the Middle East. Gold rebounded 0.5%, set to snap a three-day losing streak, while natural gas prices jumped 4.4% to a two-week high.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) edged up 1% to $97,500, marking its fourth straight week of gains.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,009.90</td>
<td>+1.7%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,052.42</td>
<td>+1.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,671.17</td>
<td>+1.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,130.34</td>
<td>+0.9%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 11:30 a.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.2% to $565.03.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.9% to $411.29.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rallied 1.4% to $488.26.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) soared 1.8% to $199.58.</li>
<li>The&nbsp;Financials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) outperformed, up 1.7%; the&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, up 0.3%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Apple Inc.: down 4.0%</li>
<li>Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): up 0.2%</li>
<li>Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>): up 0.0%</li>
<li>Chevron Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>): up 0.7%</li>
<li>Eaton Corporation plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>): down 2.1%</li>
<li>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>): down 1.8%</li>
<li>Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>): down 0.5%</li>
<li>Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>): up 3.5%</li>
<li>Monolithic Power Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>): up 4.0%</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>): up 14.2%</li>
<li>Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>): down 1.7%</li>
<li>T. Rowe Price Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>): up 3.5%</li>
<li>Cboe Global Markets, Inc. (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>): up 1.2%</li>
<li>Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>): up 1.4%</li>
<li>Live Nation Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>): up 0.1%</li>
<li>Motorola Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>): down 6.2%</li>
<li>Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>): down 0.2%</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45166673/trump-pressures-fed-after-solid-jobs-cooling-inflation-lower-rates-now">Trump Pressures Fed After Solid Jobs, Cooling Inflation: &#8216;Lower Its Rate!&#8217; (CORRECTED)</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Commodities

Econ #s

$BTC

ABNB

AMZN

CBOE

SPDR Dow Jones Industrial Average ETF Trust

MPWR

TROW

Select Sector SPDR-Consumer Discretionary

Wall Street Eyes 9th Straight Day Of Gains, Apple Falls As Chinese Sales Disappoint: What's Driving Markets Friday?

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $103 to $106.

Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $106

Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Overweight and lowers the price target from $100 to $90.

Piper Sandler Maintains Overweight on DexCom, Lowers Price Target to $90

U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Friday.
Shares of Trupanion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/quote/TRUP/earnings">raised its FY25 sales guidance</a>.
Trupanion reported quarterly loss of 3 cents per share which beat the analyst consensus estimate of loss of 5 cents per share. The company reported quarterly sales of $341.98 million which beat the analyst consensus estimate of $337.82 million.
Trupanion shares jumped 18.2% to $43.08 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares surged 30% to $9.60 after the company reported first-quarter financial results and beat its EPS and revenue estimates.</li>
<li>NPK International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPKI#NASDAQ">NPKI</a>) gained 26.6% to $7.65 after the company reported better-than-expected first-quarter financial results.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) rose 23.1% to $4.42.</li>
<li>Highest Performances Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPH#NASDAQ">HPH</a>) gained 23.1% to $7.20.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) rose 20.8% to $10.37.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) climbed 17.4% to $26.96.</li>
<li>iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) rose 17.4% to $127.43 after the company reported better-than-expected first-quarter results and raised its FY25 sales guidance</li>
<li>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) gained 15% to $460.50 after the company reported better-than-expected first-quarter financial results and raised its FY25 sales guidance.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) gained 13.7% to $79.87 following strong quarterly sales.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) jumped 12.4% to $7.74.</li>
<li>Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) gained 11.3% to $44.33 following first-quarter results.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) gained 11.1% to $52.40 after the company reported better-than-expected first-quarter sales results and raised its FY25 sales guidance.</li>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) gained 10.6% to $9.39.</li>
<li>MasTec, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) gained 6.4% to $142.68 following first-quarter results.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) rose 6.3% to $49.58.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45164963/how-to-earn-500-a-month-from-tyson-foods-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Tyson Foods Stock Ahead Of Q2 Earnings</a></li>
</ul>

Intraday Update

Markets

ACHR

ADPT

ASTS

CART

HOOD

IRTC

NPKI

PONY

TRUP

WOLF

Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday

Baird analyst Jeff Johnson maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Outperform and lowers the price target from $115 to $105.

Baird Maintains Outperform on DexCom, Lowers Price Target to $105

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) affirms FY2025 sales outlook from $4.60 billion to $4.60 billion vs $4.61 billion estimate.

Guidance

DexCom Affirms FY2025 Sales Guidance of $4.60B vs $4.61B Est

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) reported quarterly earnings of $0.32 per share which missed the analyst consensus estimate of $0.33 by 3.03 percent. This is unchanged from the same period last year. The company reported quarterly sales of $1.04 billion which beat the analyst consensus estimate of $1.02 billion by 1.83 percent. This is a 12.49 percent increase over sales of $921.00 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

DexCom Q1 Adj. EPS $0.32 Misses $0.33 Estimate, Sales $1.04B Beat $1.02B Estimate

Editor&#8217;s Note: The article has been udpated to correct the Stock Movers list.
Wall Street pushed higher in midday trading, with the S&amp;P 500 on track for its eighth consecutive gain — its longest winning streak since November 2023. The index rose about 1% to 5,560, fully recovering the losses sustained after former President Donald Trump announced <a href="https://www.benzinga.com/topic/tariffs">trade tariffs on April 2.</a>
Technology stocks led the rally, with the Nasdaq 100 climbing 1.5%. Strong and resilient corporate earnings continue to fuel investor appetite for risk, helping markets shrug off recent tariff concerns.
President Trump reassured investors, stating that progress on trade negotiations is going "very well" and that the timeline for the tax bill remains on schedule.
On the economic front, data continued to paint a weaker picture. After Wednesday's disappointing first-quarter GDP report, the ISM manufacturing PMI showed factory activity contracted for the second straight month in April. Meanwhile, price pressures surged at the fastest pace since June 2022, reflecting <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45139383/us-manufacturing-activity-contracts-in-april-as-tariffs-push-input-prices-toward-3-year-highs">inflationary effects from tariffs.</a>
Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>) was a standout gainer, soaring 8.60% after delivering a blowout quarter that beat expectations across the board, reinforcing its leadership in cloud and AI. The stock reached its highest level since late January.
Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) also topped estimates, with shares climbing more than 4%.
Sector-wise, technology outperformed, while health care lagged. Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) plunged over 9% after the pharmaceutical giant cut its 2025 guidance.
Crude oil erased early losses, rebounding to $58 per barrel after briefly dipping below $57. Gold slipped 2.2% to a two-week low.
The U.S. dollar strengthened to its highest level in over two weeks, bolstered by manufacturing surveys showing rising input costs tied to tariffs.
Treasury yields climbed for a second straight session, with the 10-year yield rising to 4.21%.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) surged past the $97,000 mark, hitting its highest level in over two months.
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>% chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,853.70</td>
<td>+ 1.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,614.89</td>
<td>+ 0.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,971.76</td>
<td>+ 0.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,802.25</td>
<td>+ 0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1% to $560.02.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.5% to $408.25.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 1.6% to $483.23.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.5% higher to $195.71.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 2.6%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 2.3%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
Stocks reacting to earnings reports included: Microsoft Corporation: up 8.30% Meta Platforms, Inc.: up 4.29% Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>): &#8211; 9.88% Mastercard Incorporated&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>): -0.20% McDonald's Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>): -1.24% Linde plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>): -1.14% Qualcomm Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>): -8.28% KKR &amp; Co. Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>): up 1.19% The Southern Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>): up 0.22% Intercontinental Exchange, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>): up 1.83% KLA Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>): -2.43% CVS Health Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>): up 6.23% Equinix, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>): -0.16% Parker-Hannifin Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>): up 0.70% Air Products and Chemicals, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>): -0.09% Howmet Aerospace Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>): up 7.44% Carrier Global Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>): up 11% Aflac Incorporated&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>): -4% Public Storage&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>): -0.18% The Allstate Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>): -1.27% MetLife, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MET#NYSE">MET</a>): up 0.47% W.W. Grainger, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>): Up 2.14% Becton, Dickinson and Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>): -15.73% Quanta Services, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>): up 10.10% Exelon Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>): -0.33% Dominion Energy, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>): up 0.91%
Stocks slated to report earnings after the bell include Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>), Airbnb Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), Atlassian Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>), Motorola Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>), EOG Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>), American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), Consolidated Edison Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>), Ingersoll Rand Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IR#NYSE">IR</a>), DexCom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), Monolithic Power Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>), Ameren Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>), GoDaddy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>), Mettler-Toledo International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>), MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>), Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>), Mohawk Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>), Camden Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPT#NYSE">CPT</a>) and Live Nation Entertainment Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>).
Read Now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45117801/apple-q2-earnings-preview-analysts-remain-bullish-with-caution-of-tariff-tornado-hitting-iphone">Apple Q2 Earnings Preview: Analysts Remain Bullish But Warn Of &#8216;Tariff Tornado&#8217; Hitting iPhone</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

EQIX

GDDY

HOLX

KLAC

MSFT

MSTR

QCOM

Wall Street Eyes 8th Positive Day As S&P 500 Recoups Tariff-Led Losses, Bitcoin Rallies To $97,000: What's Driving Markets Thursday? (CORRECTED)

AAMI

ACCO

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMWL

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

ECVT

ELME

Earnings Scheduled For May 1, 2025

In the current market session, DexCom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) share price is at $71.25, after a 0.57% decrease. Over the past month, the stock spiked by 5.85%, but over the past year, it actually fell by 44.07%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1745870418_0_0.png" alt="Past Year Chart" />

<h3>How Does DexCom P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
DexCom has a lower P/E than the aggregate P/E of 57.68 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745870418_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

A Look Into DexCom Inc's Price Over Earnings

WIIM

TNDM

Shares of diabetes stocks are trading lower following successful obesity data from Lilly.

DexCom's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NYSE">DXCM</a>) short percent of float has risen 8.43% since its last report. The company recently reported that it has 11.01 million shares sold short, which is 3.6% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.74 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>DexCom Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744383625_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for DexCom has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing DexCom's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, DexCom's peer group average for short interest as a percentage of float is 4.38%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About DexCom?

The U.S. Food and Drug Administration approved DexCom, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) Dexcom G7 15-Day Continuous Glucose Monitoring System for people <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44732771/dexcom-g7-15-day-receives-fda-clearance-the-longest-lasting-wearable-and-most-accurate-cgm-system" rel="noreferrer noopener">over 18 with diabetes</a>.
With an overall Mean Absolute Relative Difference (MARD) of 8.0%, Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia, and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">increase time in range</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry" rel="noreferrer noopener">Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry</a>
New with Dexcom G7 15 Day
<ul>
<li>Longest lasting CGM system with 15.5 days of wear.</li>
<li>Easier glucose management with fewer monthly sensors and reduced monthly waste.</li>
</ul>
Dexcom G7 features included with Dexcom G7 15 Day
<ul>
<li>The only waterproof CGM available.</li>
<li>Manage diabetes hands-free. The sensor connects directly to the patient&#8217;s Apple Watch.</li>
<li>Automated activity logging, simplified meal logging, and new medication logging to better understand how activity, food, and medications impact your glucose in real time.</li>
<li>12-hour grace period to replace finished sensors for a more seamless transition between sessions.</li>
<li>Simple mobile app with Dexcom Clarity integration to easily view glucose patterns, trends, and statistics via various interactive reports.</li>
<li>Ability to remotely share glucose numbers with caregivers and loved ones for added support and peace of mind.</li>
<li>Enhanced and customizable alert settings for improved discretion.</li>
</ul>
Dexcom is working closely with its insulin pump partners to ensure that Dexcom G7 15 Day will be compatible with automated insulin delivery systems upon launch.
Dexcom G7 15 Day is expected to launch in the U.S. in the second half of 2025.
Price Action: DXCM stock is up 0.22% at $66.99 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44721086/annexons-investigational-drug-shows-rapid-recovery-and-durable-benefit-in-rare-neurological-disorder" target="_blank" rel="noreferrer noopener">Annexon&#8217;s Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder</a></li>
</ul>

Health Care

General

FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch

Press Releases

Dexcom Appoints Jon Coleman as Chief Commercial Officer

Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.

Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System

Legal

Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders

DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U

Kuehn Law Encourages Investors of DexCom, Inc. to Contact Law Firm

Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program

Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO

Comments

DexCom

Intérêt court

DexCom (NASDAQ:DXCM) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL